
MHRA recall M&A Pharmachem’s paracetamol due to fungal contamination
pharmafile | June 18, 2019 | News story | Manufacturing and Production | Contamination, MHRA, fungal, paracetamol, pharma
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has issued a recall of M&A Pharmachem’s 500mg paracetamol tablets.
The tablets, which were produced in two separate batches of one thousand each, were found to be contaminated with the fungi Penicillium citrinium and Penicillium brevicompactum.
A number of tablets in each batch were found to be discoloured due to the fungal contamination.
However officials believe that patients have not taken the drugs as the discolouration is noticeable on opening the pack.
Wholesalers and healthcare professionals have been advised to stop supplying the affected batches as a quarantine has been put in place so that any remaining stock can be sent back to the supplier.
Louis Goss
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

MHRA authorises Lynkuet for hot flushes linked to breast cancer therapy
The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised an extension to the indication …






